Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 604749101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Janus Henderson Group Ltd. 13G/A Amendment 10 | 9.7% |
8/13/2026
Event 6/30/2026
|
|
|
FMR LLC
13G
|
6.2% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 6.2% | ||
| Abigail P. Johnson | 6.2% | ||
| BlackRock, Inc. 13G/A Amendment 2 | 5.7% |
4/27/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
| Janus Henderson Group PLC 13G/A Amendment 7 | 11.8% |
2/17/2026
Event 12/31/2025
|
|
|
Eventide Asset Management, LLC
13G/A
Amendment 4
|
4.1% |
2/13/2026
Event 12/31/2025
|
|
| Eventide Asset Management, LLC | 4.1% | ||
| Finny Kuruvilla, M.D. Ph. D. | 4.1% | ||
| Robin C. John | 4.1% | ||
|
Frazier Life Sciences IX, L.P.
13D/A
Amendment 8
|
6.8% |
1/27/2026
Event 1/23/2026
|
|
| Frazier Life Sciences IX, L.P. | 5.9% | ||
| FHMLS IX, L.P. | 5.9% | ||
| FHMLS IX, L.L.C. | 5.9% | ||
| Frazier Life Sciences X, L.P. | 0.8% | ||
| FHMLS X, L.P. | 0.8% | ||
| FHMLS X, L.L.C. | 0.8% | ||
| Frazier Life Sciences Public Fund, L.P. | 4.2% | ||
| FHMLSP, L.P. | 4.2% | ||
| FHMLSP, L.L.C. | 4.2% | ||
| Frazier Life Sciences XI, L.P. | 1.8% | ||
| FHMLS XI, L.P. | 1.8% | ||
| FHMLS XI, L.L.C. | 1.8% | ||
| Frazier Life Sciences XII, L.P. | 0.1% | ||
| FHMLS XII, L.P. | 0.1% | ||
| FHMLS XII, L.L.C. | 0.1% | ||
| James N. Topper | 6.7% | ||
| Patrick J. Heron | 6.8% | ||
| Janus Henderson Group PLC 13G/A Amendment 7 | 10.6% |
12/5/2025
Event 11/28/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 6 | 10.0% |
11/14/2025
Event 9/30/2025
|
|
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
3.0% |
11/14/2025
Event 9/30/2025
|
|
| Biotechnology Value Fund L P | 1.5% | ||
| BVF I GP LLC | 1.5% | ||
| Biotechnology Value Fund II LP | 1.2% | ||
| BVF II GP LLC | 1.2% | ||
| Biotechnology Value Trading Fund OS LP | 0.2% | ||
| BVF Partners OS Ltd. | 0.2% | ||
| BVF GP Holdings LLC | 2.8% | ||
| BVF Partners L P/IL | 3.0% | ||
| BVF Inc/IL | 3.0% | ||
| Lampert Mark N | 3.0% | ||
|
Frazier Life Sciences IX, L.P.
13D/A
Amendment 7
|
7.6% |
11/4/2025
Event 11/1/2025
|
|
| Frazier Life Sciences IX, L.P. | 7.1% | ||
| FHMLS IX, L.P. | 7.1% | ||
| FHMLS IX, L.L.C. | 7.1% | ||
| Frazier Life Sciences X, L.P. | 0.3% | ||
| FHMLS X, L.P. | 0.3% | ||
| FHMLS X, L.L.C. | 0.3% | ||
| Frazier Life Sciences Public Fund, L.P. | 5.0% | ||
| FHMLSP, L.P. | 5.0% | ||
| FHMLSP, L.L.C. | 5.0% | ||
| Frazier Life Sciences XI, L.P. | 1.1% | ||
| FHMLS XI, L.P. | 1.1% | ||
| FHMLS XI, L.L.C. | 1.1% | ||
| James N. Topper | 7.4% | ||
| Patrick J. Heron | 7.6% | ||
|
Frazier Life Sciences IX, L.P.
13D/A
Amendment 6
|
7.6% |
8/20/2025
Event 8/18/2025
|
|
| Frazier Life Sciences IX, L.P. | 7.1% | ||
| FHMLS IX, L.P. | 7.1% | ||
| FHMLS IX, L.L.C. | 7.1% | ||
| Frazier Life Sciences X, L.P. | 0.3% | ||
| FHMLS X, L.P. | 0.3% | ||
| FHMLS X, L.L.C. | 0.3% | ||
| Frazier Life Sciences Public Fund, L.P. | 3.1% | ||
| FHMLSP, L.P. | 3.1% | ||
| FHMLSP, L.L.C. | 3.1% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 1.9% | ||
| FHMLSP Overage, L.P. | 1.9% | ||
| FHMLSP Overage, L.L.C. | 1.9% | ||
| Frazier Life Sciences XI, L.P. | 1.1% | ||
| FHMLS XI, L.P. | 1.1% | ||
| FHMLS XI, L.L.C. | 1.1% | ||
| James N. Topper | 7.4% | ||
| Patrick J. Heron | 7.6% | ||
| Albert Cha | 0% | ||
| James Brush | 0% | ||
| Daniel Estes | 0% | ||
| Janus Henderson Group PLC 13G/A Amendment 5 | 10.6% |
8/14/2025
Event 6/30/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 5 | 10.3% |
6/6/2025
Event 5/30/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 4 | 9.7% |
5/15/2025
Event 3/31/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 3 | 10.1% |
5/7/2025
Event 4/30/2025
|
|
|
Eventide Asset Management, LLC
13G/A
Amendment 3
|
5.4% |
2/14/2025
Event 12/31/2024
|
|
| Eventide Asset Management, LLC | 5.4% | ||
| Finny Kuruvilla, M.D., Ph. D. | 5.4% | ||
| Robin C. John | 5.4% | ||
| Janus Henderson Group PLC 13G/A Amendment 2 | 9.5% |
2/14/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 6 | 6.70 k | $573 k |
| 2026 Q2 | 337 | 77.1 M | $8.41 B |
| 2026 Q1 | 321 | 68.3 M | $6.29 B |
| 2025 Q4 | 292 | 61.0 M | $4.82 B |
| 2025 Q3 | 284 | 57.7 M | $4.23 B |
| 2025 Q2 | 223 | 56.0 M | $2.85 B |
| 2025 Q1 | 222 | 54.2 M | $2.44 B |
| 2024 Q4 | 211 | 53.0 M | $2.19 B |
| 2024 Q3 | 191 | 53.4 M | $2.08 B |
| 2024 Q2 | 174 | 54.4 M | $1.86 B |
| 2024 Q1 | 185 | 54.1 M | $1.36 B |
| 2023 Q4 | 203 | 51.8 M | $1.53 B |
| 2023 Q3 | 166 | 48.9 M | $1.55 B |
| 2023 Q2 | 152 | 36.9 M | $956 M |
| 2023 Q1 | 121 | 34.7 M | $833 M |
| 2022 Q4 | 108 | 35.1 M | $685 M |
| 2022 Q3 | 115 | 34.6 M | $727 M |
| 2022 Q2 | 113 | 30.2 M | $587 M |
| 2022 Q1 | 105 | 27.8 M | $612 M |
| 2021 Q4 | 94 | 24.8 M | $396 M |
| 2021 Q3 | 77 | 23.3 M | $465 M |
| 2021 Q2 | 70 | 24.1 M | $416 M |
| 2021 Q1 | 63 | 23.4 M | $463 M |
| 2020 Q4 | 74 | 23.9 M | $418 M |
| 2020 Q3 | 52 | 18.7 M | $361 M |
| 2020 Q2 | 60 | 19.0 M | $369 M |
| 2020 Q1 | 46 | 18.8 M | $263 M |
| 2019 Q4 | 41 | 16.3 M | $400 M |
| 2019 Q3 | 40 | 16.5 M | $166 M |